AI for De Novo Drug Design Global Market Report 2026

The artificial intelligence (AI) for de novo drug design market size has grown exponentially in recent years. It will grow from $1.9 billion in 2025 to $2.53 billion in 2026 at a compound annual growth rate (CAGR) of 33.4%. The growth in the historic period can be attributed to high r&d costs in traditional drug discovery, growing demand for faster drug development, adoption of computational chemistry tools, increasing pharmaceutical investments, expansion of academic and research collaborations.

The artificial intelligence (AI) for de novo drug design market size is expected to see exponential growth in the next few years. It will grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 33.7%. The growth in the forecast period can be attributed to growing adoption of ai-driven lead compound generation, increasing use of admet prediction models, rising integration of cloud and on-premises deployment, expansion of model development and data annotation services, growing collaboration between pharmaceutical and biotech companies. Major trends in the forecast period include increasing adoption of cloud-based ai platforms, rising demand for deep learning-based drug design software, growing integration of workflow automation in drug discovery, expansion of molecular property prediction tools, rising focus on targeted therapeutic area applications.

The rising prevalence of complex diseases is projected to accelerate the growth of the artificial intelligence (AI) for the de novo drug design market moving forward. Complex diseases are health disorders resulting from a combination of genetic, environmental, and lifestyle influences, often affecting multiple body systems and requiring advanced or prolonged medical care. The prevalence of complex diseases is increasing due to unhealthy lifestyle behaviors, which heighten the likelihood of chronic conditions such as diabetes, cardiovascular disorders, and certain types of cancer. Artificial intelligence (AI) for de novo drug design advances the discovery of innovative therapies by processing complex biological datasets and forecasting effective drug candidates, thereby addressing the difficulties associated with multifactorial and long-term complex diseases. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are anticipated by 2050, reflecting a 77% increase compared to the estimated 20 million cases recorded in 2022. Therefore, the rising prevalence of complex diseases is driving the growth of the artificial intelligence (AI) for de novo drug design market.

Key companies operating in the artificial intelligence (AI) for de novo drug design market are focusing on developing innovative solutions, such as artificial intelligence (AI)-native drug discovery platforms, to accelerate the design and optimization of novel small molecules. Artificial intelligence (AI)-native drug discovery platforms are integrated systems that use AI models to generate, predict, and select novel molecules from scratch, helping accelerate drug discovery by identifying promising compounds faster and more efficiently than traditional trial-and-error methods. For example, in November 2025, Terray Therapeutics, a US-based biotechnology company, launched EMMI (Experimentation Meets Machine Intelligence), an AI-native drug discovery platform specifically engineered for de novo small molecule design. It integrates Terray Therapeutics’ proprietary ultra-miniaturized experimental hardware with a highly automated laboratory environment and the Chemistry-Oriented AI Transformer Interface, third generation (COATI3) chemistry foundation model, to generate millions of novel molecules, predict their potency, identify the most promising candidates, and iteratively refine them. The platform’s generative AI leverages reinforcement learning to propose synthetically accessible molecules, while predictive AI models rapidly assess properties such as potency, selectivity, solubility, metabolism, and clearance, and the selection AI determines which molecules to synthesize to reduce time and cost by up to threefold compared to industry standards. EMMI has applications across internal immunology programs as well as strategic partnerships targeting previously unexplored chemical space, making it a transformative solution for de novo drug design.

In July 2023, BioNTech SE, a Germany-based biopharmaceutical technology company, finalized the acquisition of InstaDeep Ltd. for $549 million (€500 million). With this acquisition, BioNTech intended to reinforce and broaden its strategic capabilities in artificial intelligence-enabled drug discovery and development by incorporating advanced AI and machine learning technologies to speed up the creation of next-generation immunotherapies and vaccines. InstaDeep Ltd. is a UK-based technology company that focuses on delivering advanced artificial intelligence and machine learning solutions that facilitate de novo drug design.

Major companies operating in the artificial intelligence (AI) for de novo drug design market are Schrödinger Inc., XtalPi Holdings Ltd., Owkin Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Deep Genomics Inc., Iktos SA, Atomwise Inc., Terray Therapeutics Inc., Evogene Ltd., Genesis Therapeutics Inc., Insitro Inc., Verge Genomics Inc., DeepCure Inc., Cloud Pharmaceuticals Inc., Gero LLC, Chai Discovery Inc., Latent Labs Ltd., BioAge Labs Inc., Peptone Ltd., Generate Biomedicines Inc.

North America was the largest region in the artificial intelligence (AI) for de novo drug design market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) for de novo drug design market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) for de novo drug design market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI) for de novo drug design market consists of revenues earned by entities by providing services such as molecular design and generation, target identification and validation, lead optimization, predictive modeling and simulation, data analysis and integration, and virtual screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Artificial intelligence (AI) for de novo drug design involves using machine learning and computational algorithms to generate novel molecular structures with targeted biological properties. It employs pattern recognition, predictive modeling, and optimization techniques to efficiently explore vast chemical spaces. AI-driven approaches accelerate the discovery of potential drug candidates while reducing reliance on conventional trial-and-error methods.

The primary components of artificial intelligence (AI) for de novo drug design include software and services. Software platforms leverage AI algorithms to accelerate drug discovery, including target identification and lead compound optimization. Therapeutic areas include oncology, neurological disorders, infectious diseases, cardiovascular diseases, rare diseases, metabolic disorders, and other indications. Deployment occurs via on-premises and cloud-based solutions, serving applications such as target identification, lead compound generation, molecular property prediction, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, and others, with end users including pharmaceutical companies, biotechnology firms, academic and research institutes, contract research organizations, and other sectors.

Tariffs on imported computational hardware, specialized AI processors, and molecular modeling software components are impacting the AI for de novo drug design market by increasing costs for software providers and research organizations. Segments such as cloud-based software and deep learning platforms, especially in North America, Europe, and Asia-Pacific, are most affected. While tariffs elevate operational expenses, they also incentivize domestic hardware production, regional software development, and innovation in cost-efficient AI drug design platforms, enhancing local capabilities and supply chain resilience.

The artificial intelligence (AI) for de novo drug design market research report is one of a series of new reports that provides artificial intelligence (AI) for de novo drug design market statistics, including artificial intelligence (AI) for de novo drug design industry global market size, regional shares, competitors with a artificial intelligence (AI) for de novo drug design market share, detailed artificial intelligence (AI) for de novo drug design market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) for de novo drug design industry. This artificial intelligence (AI) for de novo drug design market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.